XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3

Segments (Tables)

9 Months Ended

Sep. 30, 2024

Summary of Segment Profit

 

a. Segment information:

		Three months ended September 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,225			$	1,265			$	613
Gross profit			1,265				698				306
R&D expenses			151				55				27
S&M expenses			259				203				134
G&A expenses			107				67				36
Other loss (income)			§				1				§
Segment profit		$	748			$	373			$	109

§ Represents an amount less than $0.5 million.

		Three months ended September 30,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,896			$	1,146			$	591
Gross profit			1,060				648				293
R&D expenses			156				62				30
S&M expenses			243				184				116
G&A expenses			93				66				33
Other loss (income)			(2	)			§				(2	)
Segment profit		$	571			$	338			$	117

§ Represents an amount less than $0.5 million.

		Nine months ended September 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	6,060			$	3,749			$	1,802
Gross profit			3,291				2,113				889
R&D expenses			475				173				85
S&M expenses			789				605				397
G&A expenses			300				197				109
Other loss (income)			(1	)			1				(1	)
Segment profit		$	1,727			$	1,137			$	299
		Nine months ended September 30,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	5,465			$	3,493			$	1,750
Gross profit			2,866				1,943				861
R&D expenses			460				168				81
S&M expenses			700				565				353
G&A expenses			289				196				105
Other loss (income)			(3	)			(2	)			(34	)
Segment profit		$	1,421			$	1,017			$	356

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2024 and 2023:

		Three months ended								Nine months ended
		September 30,								September 30,
		2024				2023				2024				2023
		(U.S. $ in millions)								(U.S. $ in millions)
United States profit		$	748			$	571			$	1,727			$	1,421
Europe profit			373				338				1,137				1,017
International Markets profit			109				117				299				356
Total reportable segments profit			1,230				1,025				3,163				2,794
Profit (loss) of other activities			(16	)			(5	)			(1	)			22
Total segments profit			1,214				1,020				3,162				2,816
Amounts not allocated to segments:
Amortization			146				145				444				471
Other assets impairments, restructuring and other items*			(23	)			57				931				276
Goodwill impairment			600				—				1,000				700
Intangible assets impairments			28				47				169				289
Legal settlements and loss contingencies			450				314				638				1,009
Other unallocated amounts			64				112				254				394
Consolidated operating income (loss) *			(51	)			344				(274	)			(323	)
Financial expenses, net			272				280				763				808
Consolidated income (loss) before income taxes *		$	(324	)		$	64			$	(1,037	)		$	(1,131	)

* The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three and nine months ended September 30, 2024 and 2023:

United States		Three months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,094			$	839
AJOVY®			58				56
AUSTEDO			435				339
BENDEKA® and TREANDA®			40				56
COPAXONE			69				98
UZEDY			35				2
Anda			380				367
Other			115				140
Total		$	2,225			$	1,896

United States		Nine months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	2,924			$	2,471
AJOVY			144				154
AUSTEDO			1,124				817
BENDEKA and TREANDA			127				185
COPAXONE			179				224
UZEDY			75				14
Anda			1,134				1,183
Other			352				417
Total		$	6,060			$	5,465

Europe		Three months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	973			$	886
AJOVY			56				41
COPAXONE			53				55
Respiratory products			60				61
Other*			124				104
Total		$	1,265			$	1,146

* Other revenues in the third quarter of 2024 include the sale of certain product rights.

Europe		Nine months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	2,947			$	2,727
AJOVY			158				115
COPAXONE			163				174
Respiratory products			183				195
Other*			299				282
Total		$	3,749			$	3,493

* Other revenues in the first nine months of 2024 include the sale of certain product rights.

International markets		Three months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	477			$	470
AJOVY			24				18
COPAXONE			13				16
Other*			99				87
Total		$	613			$	591

* Other revenues in the third quarter of 2024 include the sale of certain product rights.

International markets		Nine months ended September 30,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,440			$	1,425
AJOVY			63				45
COPAXONE			38				50
Other*			261				229
Total		$	1,802			$	1,750

* Other revenues in the first nine months of 2024 include the sale of certain product rights.

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration